Back to top
more

Penumbra (PEN)

(Real Time Quote from BATS)

$201.53 USD

201.53
336,365

-4.62 (-2.24%)

Updated Apr 25, 2024 09:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial

by Zacks Equity Research

Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.

Penumbra's (PEN) Expansion Moves, New Launches Aid Growth

by Zacks Equity Research

Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.

Here's Why Investors Should Hold Encompass Health (EHC) Now

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Wall Street Analysts Think Penumbra (PEN) Could Surge 37.71%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Penumbra (PEN) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down -11.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Penumbra (PEN)

by Zacks Equity Research

Penumbra (PEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.

Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails

by Zacks Equity Research

Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.

Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

Innovator of neurovascular stroke technologies with 980% EPS growth is a buying opportunity

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Encompass Health (EHC) Up 41% in a Year: More Room for Growth?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Nilanjan Banerjee headshot

Buy These 3 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Strategic Education (STRA) and Huron (HURN) are poised to gain.

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Factors That Make Molina Healthcare (MOH) an Attractive Bet Now

by Zacks Equity Research

Molina Healthcare (MOH) remains well-poised for growth on a growing customer base, acquisitions and solid cash reserves.

Wall Street Analysts Believe Penumbra (PEN) Could Rally 27.69%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 27.7% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.